{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T20:12:08Z","timestamp":1760299928472},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,4,23]],"date-time":"2018-04-23T00:00:00Z","timestamp":1524441600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Vessels"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s00380-018-1177-6","type":"journal-article","created":{"date-parts":[[2018,4,23]],"date-time":"2018-04-23T11:16:30Z","timestamp":1524482190000},"page":"1204-1213","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The effects of tolvaptan dose on cardiac mortality in patients with acute decompensated heart failure after hospital discharge"],"prefix":"10.1007","volume":"33","author":[{"given":"Kenji","family":"Matsumoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoichi","family":"Ehara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Otsuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshio","family":"Kawase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,4,23]]},"reference":[{"key":"1177_CR1","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1056\/NEJM197112232852601","volume":"285","author":"PA McKee","year":"1971","unstructured":"McKee PA, Castelli WP, McNamara PM, Kannel WB (1971) The natural history of congestive heart failure: the Framingham study. N Engl J Med 285:1441\u20131446","journal-title":"N Engl J Med"},{"key":"1177_CR2","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1093\/eurheartj\/ehs104","volume":"33","author":"JJ McMurray","year":"2012","unstructured":"McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, B\u00f6hm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, K\u00f8ber L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, R\u00f8nnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, ESC Committee for Practice Guidelines (2012) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 33:1787\u20131847","journal-title":"Eur Heart J"},{"key":"1177_CR3","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.ahj.2010.05.032","volume":"160","author":"HM Abdel-Qadir","year":"2010","unstructured":"Abdel-Qadir HM, Tu JV, Yun L, Austin PC, Newton GE, Lee DS (2010) Diuretic dose and long-term outcomes in elderly patients with heart failure after hospitalization. Am Heart J 160:264\u2013271","journal-title":"Am Heart J"},{"key":"1177_CR4","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1016\/j.amjcard.2005.12.072","volume":"97","author":"S Eshaghian","year":"2006","unstructured":"Eshaghian S, Horwich TB, Fonarow GC (2006) Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol 97:1759\u20131764","journal-title":"Am J Cardiol"},{"key":"1177_CR5","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S0167-5273(99)00129-1","volume":"71","author":"KJ Harjai","year":"1999","unstructured":"Harjai KJ, Dinshaw HK, Nunez E, Shah M, Thompson H, Turgut T, Ventura HO (1999) The prognostic implications of outpatient diuretic dose in heart failure. Int J Cardiol 71:219\u2013225","journal-title":"Int J Cardiol"},{"key":"1177_CR6","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1253\/circj.CJ-14-0244","volume":"78","author":"T Imamura","year":"2014","unstructured":"Imamura T, Kinugawa K, Fujino T, Inaba T, Maki H, Hatano M, Yao A, Komuro I (2014) Increased urine aquaporin-2 relative to plasma arginine vasopressin is a novel marker of response to tolvaptan in patients with decompensated heart failure. Circ J 78:2240\u20132249","journal-title":"Circ J"},{"key":"1177_CR7","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1161\/hc4501.099313","volume":"104","author":"JE Udelson","year":"2001","unstructured":"Udelson JE, Smith WB, Hendrix GH, Painchaud CA, Ghazzi M, Thomas I, Ghali JK, Selaru P, Chanoine F, Pressler ML, Konstam MA (2001) Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 104:2417\u20132423","journal-title":"Circulation"},{"key":"1177_CR8","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1001\/jama.297.12.1332","volume":"297","author":"M Gheorghiade","year":"2007","unstructured":"Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C, Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators (2007) Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 297:1332\u20131343","journal-title":"JAMA"},{"key":"1177_CR9","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1016\/j.jacc.2007.01.091","volume":"49","author":"JE Udelson","year":"2007","unstructured":"Udelson JE, McGrew FA, Flores E, Ibrahim H, Katz S, Koshkarian G, O\u2019Brien T, Kronenberg MW, Zimmer C, Orlandi C, Konstam MA (2007) Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. J Am Coll Cardiol 49:2151\u20132159","journal-title":"J Am Coll Cardiol"},{"key":"1177_CR10","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1253\/circj.CJ-17-0554","volume":"81","author":"Y Uemura","year":"2017","unstructured":"Uemura Y, Shibata R, Takemoto K, Uchikawa T, Koyasu M, Ishikawa S, Imai R, Ozaki Y, Watanabe T, Teraoka T, Watarai M, Murohara T (2017) Safety and efficacy of long-term use of tolvaptan in patients with heart failure and chronic kidney disease. Circ J 81:1736\u20131738","journal-title":"Circ J"},{"key":"1177_CR11","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/1755-5922.12142","volume":"33","author":"T Okabe","year":"2015","unstructured":"Okabe T, Yakushiji T, Igawa W, Ono M, Kido T, Ebara S, Yamashita K, Yamamoto MH, Saito S, Hoshimoto K, Amemiya K, Isomura N, Araki H, Ochiai M (2015) The efficacy of tolvaptan in congestive heart failure patients with and without hypoalbuminemia: a pilot study. Cardiovasc Ther 33:275\u2013281","journal-title":"Cardiovasc Ther"},{"key":"1177_CR12","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/nep.12406","volume":"20","author":"K Shimizu","year":"2015","unstructured":"Shimizu K, Doi K, Imamura T, Noiri E, Yahagi N, Nangaku M, Kinugawa K (2015) Ratio of urine and blood urea nitrogen concentration predicts the response of tolvaptan in congestive heart failure. Nephrology (Carlton) 20:405\u2013412","journal-title":"Nephrology (Carlton)"},{"key":"1177_CR13","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s40256-015-0121-8","volume":"15","author":"D Okayama","year":"2015","unstructured":"Okayama D, Suzuki T, Shiga T, Minami Y, Tsuruoka S, Hagiwara N (2015) Blood urea nitrogen\/creatinine ratio and response to tolvaptan in patients with decompensated heart failure: a retrospective analysis. Am J Cardiovasc Drugs 15:289\u2013293","journal-title":"Am J Cardiovasc Drugs"},{"key":"1177_CR14","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1159\/000381859","volume":"130","author":"H Iwatani","year":"2015","unstructured":"Iwatani H, Kawabata H, Sakaguchi Y, Yamamoto R, Hamano T, Rakugi H, Isaka Y (2015) Urine osmolarity predicts the body weight-reduction response to tolvaptan in chronic kidney disease patients: a retrospective, observational study. Nephron 130:8\u201312","journal-title":"Nephron"},{"key":"1177_CR15","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jjcc.2015.04.017","volume":"67","author":"H Toda","year":"2016","unstructured":"Toda H, Nakamura K, Nakahama M, Wada T, Watanabe A, Hashimoto K, Terasaka R, Tokioka K, Nishii N, Miyoshi T, Kohno K, Kawai Y, Miyaji K, Koide Y, Tachibana M, Yoshioka R, Ito H, Investigators Tolvaptan Registry (2016) Clinical characteristics of responders to treatment with tolvaptan in patients with acute decompensated heart failure: IMPORTANCE of preserved kidney size. J Cardiol 67:177\u2013183","journal-title":"J Cardiol"},{"key":"1177_CR16","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1253\/circj.CJ-66-0068","volume":"77","author":"JCS Joint Working Group","year":"2013","unstructured":"JCS Joint Working Group (2013) Guidelines for treatment of acute heart failure (JCS 2011). Circ J 77:2157\u20132201","journal-title":"Circ J"},{"key":"1177_CR17","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1093\/eurheartj\/ehr254","volume":"33","author":"Meta-analysis Global Group in Chronic Heart Failure (MAGGIC)","year":"2012","unstructured":"Meta-analysis Global Group in Chronic Heart Failure (MAGGIC) (2012) The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J 33:1750\u20131757","journal-title":"Eur Heart J"},{"key":"1177_CR18","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1536\/ihj.16-625","volume":"59","author":"Y Nakano","year":"2018","unstructured":"Nakano Y, Mizuno T, Niwa T, Mukai K, Wakabayashi H, Watanabe A, Ando H, Takashima H, Murotani K, Waseda K, Amano T (2018) Impact of continuous administration of tolvaptan on preventing medium-term worsening renal function and long-term adverse events in heart failure patients with chronic kidney disease. Int Heart J 59:105\u2013111","journal-title":"Int Heart J"},{"key":"1177_CR19","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1007\/s00380-015-0775-9","volume":"31","author":"Y Uemura","year":"2016","unstructured":"Uemura Y, Shibata R, Takemoto K, Uchikawa T, Koyasu M, Ishikawa S, Mitsuda T, Miura A, Imai R, Iwamiya S, Ozaki Y, Kato T, Miura T, Watarai M, Murohara T (2016) Clinical benefit of tolvaptan in patients with acute decompensated heart failure and chronic kidney disease. Heart Vessels 31:1643\u20131649","journal-title":"Heart Vessels"},{"key":"1177_CR20","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s00380-016-0872-4","volume":"32","author":"A Hanatani","year":"2017","unstructured":"Hanatani A, Shibata A, Kitada R, Iwata S, Matsumura Y, Doi A, Sugioka K, Takagi M, Yoshiyama M (2017) Administration of tolvaptan with reduction of loop diuretics ameliorates congestion with improving renal dysfunction in patients with congestive heart failure and renal dysfunction. Heart Vessels 32:287\u2013294","journal-title":"Heart Vessels"},{"key":"1177_CR21","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1007\/s00380-015-0780-z","volume":"31","author":"R Matsukawa","year":"2016","unstructured":"Matsukawa R, Kubota T, Okabe M, Yamamoto Y (2016) Early use of V2 receptor antagonists is associated with a shorter hospital stay and reduction in in-hospital death in patients with decompensated heart failure. Heart Vessels 31:1650\u20131658","journal-title":"Heart Vessels"},{"key":"1177_CR22","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jjcc.2015.09.020","volume":"67","author":"K Kimura","year":"2016","unstructured":"Kimura K, Momose T, Hasegawa T, Morita T, Misawa T, Motoki H, Izawa A, Ikeda U (2016) Early administration of tolvaptan preserves renal function in elderly patients with acute decompensated heart failure. J Cardiol 67:399\u2013405","journal-title":"J Cardiol"},{"key":"1177_CR23","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/eurheartj\/ehs444","volume":"34","author":"AP Ambrosy","year":"2013","unstructured":"Ambrosy AP, Pang PS, Khan S, Konstam MA, Fonarow GC, Traver B, Maggioni AP, Cook T, Swedberg K, Burnett JC Jr, Grinfeld L, Udelson JE, Zannad F, Gheorghiade M, Trial Investigators EVEREST (2013) Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial. Eur Heart J 34:835\u2013843","journal-title":"Eur Heart J"},{"key":"1177_CR24","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/ehf2.12088","volume":"3","author":"K Jujo","year":"2016","unstructured":"Jujo K, Saito K, Ishida I, Furuki Y, Kim A, Suzuki Y, Sekiguchi H, Yamaguchi J, Ogawa H, Hagiwara N (2016) Randomized pilot trial comparing tolvaptan with furosemide on renal and neurohumoral effects in acute heart failure. ESC Heart Fail 3:177\u2013188","journal-title":"ESC Heart Fail"},{"key":"1177_CR25","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1536\/ihj.16-249","volume":"58","author":"K Kinugawa","year":"2017","unstructured":"Kinugawa K, Inomata T, Sato N, Yasuda M, Shimakawa T, Bando K, Fukuta Y (2017) Who needs longer tolvaptan treatment? Int Heart J 58:30\u201335","journal-title":"Int Heart J"},{"key":"1177_CR26","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","volume":"297","author":"MA Konstam","year":"2007","unstructured":"Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C, Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators (2007) Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 297:1319\u20131331","journal-title":"JAMA"},{"key":"1177_CR27","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1007\/s00228-017-2302-7","volume":"73","author":"SE Shoaf","year":"2017","unstructured":"Shoaf SE, Bricmont P, Dandurand A (2017) Low-dose tolvaptan PK\/PD: comparison of patients with hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion to healthy adults. Eur J Clin Pharmacol 73:1399\u20131408","journal-title":"Eur J Clin Pharmacol"}],"container-title":["Heart and Vessels"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00380-018-1177-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00380-018-1177-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00380-018-1177-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,22]],"date-time":"2019-04-22T23:36:40Z","timestamp":1555976200000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00380-018-1177-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,23]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["1177"],"URL":"https:\/\/doi.org\/10.1007\/s00380-018-1177-6","relation":{},"ISSN":["0910-8327","1615-2573"],"issn-type":[{"value":"0910-8327","type":"print"},{"value":"1615-2573","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,23]]},"assertion":[{"value":"15 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in this study were conducted with the patients\u2019 informed consent, and complied with the national ethical guidelines for medical and health research involving human subjects and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}}]}}